New iPSC Lines Added in 2022

02/2023

Induced pluripotent stem cells (iPSCs) offer hope to patients and promise to scientists due to their potential in disease pathology research and highly targeted therapies to improve health outcomes.

Our team has the core capabilities to maintain, characterize, bank, and distribute the highest quality iPSCs and our laboratories operate under the most stringent ISO 9001:2015 certified standard operating procedures, including the performance of quality control testing and assessment of pluripotency.

Below is the list of all new iPSC lines that were added to the Coriell biobank in 2022.

ID numberDiagnosis
AG28346Non-Wound Healing Phenotype
GM28374Neuroaxonal Dystrophy, Infantile
GM28227Neiman Pick Type C1
GM28229Glycogen Storage Disease Type II
AG28369Non-Wound Healing Phenotype
AG28462Rothmund-Thomson Syndrome
GM28259Tay Sachs Disease
AG28336Parkinson Disease
GM28404Apparently Healthy
GM28383Scheie Syndrome
GM28385Fibrodysplasia Ossificans Progressiva
AG28409Xeroderm Pigmentosum
GM28558Alagille Syndrome 1
GM27620Rett Syndrome, Congenital Variant (FOXG1)
GM28380Ceroid lipofuscinosis Neuronal 2, Late infantile
GM28559Alagille Syndrome 1
GM27624Rett Syndrome, Congenital Variant (FOXG1)
GM28589Cerebral Creatine Deficiency Syndrome 3
GM28622Glycogen Storage Disease Type II
AG28599Parkinson Disease
GM28399Neuropathy, Hereditary Sensory and Autonomic, Type III
GM28575Rett Syndrome, Congenital Variant (FOXG1)
GM28576Rett Syndrome, Congenital Variant (FOXG1)
GM28577Rett Syndrome, Congenital Variant (FOXG1)
GM28578Rett Syndrome, Congenital Variant (FOXG1)
AG28585Cockayne Syndrome Type A
GM28603Zinc-finger C4H2 Deficiency ZC4H2
AG28851Apparently Healthy
AG28869Apparently Healthy
GM28862Leigh Syndrome

Other News